lunedì, 4 maggio 2026

Notizie AIOM – anno XV

27 Settembre 2017

Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2

An integrated analysis was undertaken to characterize the antitumor activity and safety profile of the oral poly(ADP-ribose) polymerase inhibitor rucaparib in patients with relapsed high-grade ovarian carcinoma (HGOC). Eligible patients from Study 10 (NCT01482715) and ARIEL2 ...
Leggi tutto

27 Settembre 2017

Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case-control study

Refining the selection of metastatic colorectal cancer (mCRC) patients candidates for anti-EGFR monoclonal antibodies beyond RAS and BRAF testing is a challenge of precision oncology. Several uncommon genomic mechanisms of primary resistance, leading to activation of tyrosine ...
Leggi tutto

27 Settembre 2017

Sarcopenia Is Associated with Quality of Life and Depression in Patients with Advanced Cancer

Patients with advanced cancer often experience muscle wasting (sarcopenia), yet little is known about the characteristics associated with sarcopenia and the relationship between sarcopenia and patients' quality of life (QOL) and mood. As part of a randomized trial, we assessed ...
Leggi tutto

27 Settembre 2017

Web-app

Una nuova web-app gratuita, in otto lingue, per computer, tablet e smartphone sul tumore del pancreas è disponibile sul sito del Corriere della Sera in collaborazione con l'Associazione Italiana di Oncologia Medica (leggi e scarica). Strumento interattivo in due versioni, ...
Leggi tutto

26 Settembre 2017

MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy

MONARCH 2 (ClinicalTrials.gov identifier: NCT02107703) compared the efficacy and safety of abemaciclib, a selective cyclin-dependent kinase 4 and 6 inhibitor, plus fulvestrant with fulvestrant alone in patients with advanced breast cancer (ABC). MONARCH 2 was a global, double-blind, ...
Leggi tutto

26 Settembre 2017

Through the ASCO Lens: A Perspective on the Present and Future of Oncology

September 23, 2017 - The clinical oncology community, along with patients, families, pharmaceutical companies, investors, and third-party payers, eagerly awaits the plenary session presentations at the American Society of Clinical Oncology (ASCO) annual meetings as representing ...
Leggi tutto

26 Settembre 2017

FDA Approves Nivolumab for Hepatocellular Carcinoma

September 22, 2017 - The FDA has granted an accelerated approval to nivolumab for the treatment of patients with hepatocellular carcinoma (HCC) following prior sorafenib, regardless of PD-L1 status. The approval is based on 154 patients enrolled in the phase I/II CheckMate-040 ...
Leggi tutto

25 Settembre 2017

FDA Approves Pembrolizumab for PD-L1+ Gastric Cancer

September 22, 2017 - The FDA has approved pembrolizumab for the treatment of patients with PD-L1–positive recurrent or advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received 2 or more lines of chemotherapy, including fluoropyrimidine- ...
Leggi tutto

22 Settembre 2017

Avelumab Approved in Europe for Merkel Cell Carcinoma

September 21, 2017 - The European Commission (EC) has approved avelumab for the treatment of patients with metastatic Merkel cell carcinoma, according to Merck KGaA and Pfizer, the co-developers of the PD-L1 inhibitor. Avelumab is approved for this indication in all 28 EU ...
Leggi tutto

22 Settembre 2017

22 settembre 2017 – AIFA: vaccini influenzali per la stagione 2017-2018